Ono Pharmaceutical Co., Ltd. (Osaka, Japan; “Ono”) and Seikagaku Corporation (Tokyo, Japan; “Seikagaku”) announced today that Seikagaku has obtained from the Ministry of Health, Labour and Welfare (MHLW) a manufacturing and marketing approval in Japan for JOYCLU® 30mg Intra-articular Injection (generic name: diclofenac etalhyaluronate sodium; development code: ONO-5704/SI-613; “JOYCLU”) for the indication of osteoarthritis (knee joint and hip joint).
Ono Pharmaceutical Co., Ltd. (Osaka, Japan; “Ono”) and Seikagaku Corporation (Tokyo, Japan; “Seikagaku”) announced today that the results from a Phase III clinical study of ONO-5704/SI-613 in Japan in patients with knee osteoarthritis (“the Study”) were presented at the 93rd Annual Meeting of the Japanese Orthopaedic Association, an on-line annual meeting being held from Thursday June 11 to Monday August 31, 2020. ONO-5704/SI-613 is being jointly developed in Japan by the companies for the treatment of osteoarthritis.
TOKYO, Apr 1, 2020 - (JCN Newswire) - Eisai Co., Ltd. and Seikagaku announced today that the companies have entered into an agreement for the co-development and marketing alliance in China for SI-613 (diclofenac conjugated sodium hyaluronate), a therapeutic agent for osteoarthritis discovered by Seikagaku.
Japanese drugmaker Seikagaku has taken a step towards lining up a big pharma partner for its phase 3 osteoarthritis drug SI-613, with Ono taking an option on the drug.